Abstract
Recent studies show that lncRNAs involve in the initiation and progression of various cancers including osteosarcoma (OS). IncRNA Xist has been verified as an oncogene in several human cancers, and its abnormal expression was closely associated with tumor initiation and progression. Nevertheless, the role of Xist in OS remains unclear. Here, we revealed the Xist expression level was up-regulated in OS tissues and discovered that Xist knockdown significantly repressed OS cell proliferation. Additionally, mechanistic analysis revealed that Xist can repress P21 expression to regulate OS cell cycle and proliferation by binding to EZH2. Taking all into account, Xist may function in promoting OS cell proliferation and may potentially serve as a novel biomarker and therapeutic target for OS.
Highlights
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults, about 80 percent of OS occurs in the long bones of the limbs, most often at the metaphysis of the long bones around the knee, and the other 20 percent occurs in the axial bone and pelvis [1]
The expression level of X-inactive specific transcript (Xist) was measured by qRT-PCR and the results showed that Xist was expressed at higher levels in OS tissues compared with corresponding noncancerous tissues (Figure 1A)
The results showed that the Xist level was remarkably correlated with tumor size (P = 0.034) and there was no relationship between Xist expression level and age, gender, location, clinical stage or distant metastasis (Table 1)
Summary
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults, about 80 percent of OS occurs in the long bones of the limbs, most often at the metaphysis of the long bones around the knee, and the other 20 percent occurs in the axial bone and pelvis [1]. OS is a high metastatic potential tumor, and the most common targets are the lung and other bones [3, 4]. There are a large number of OS patients experienced distant metastasis or local relapse after intensive chemotherapy and curative resection of the primary tumor [5]. There is an urgent need to explore the potential molecular mechanisms in OS and it is critical to identify new biomarkers and therapeutic targets
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
